LAURA OLSON: Open Payments
NPI 1255703799 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,080 in 146 payments from 28 companies in 2025. Trend: 2023 $415 · 2024 $2,377 · 2025 $3,080
Food & beverage: $3,080
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 23 | $458 |
| Amgen Inc. | 21 | $312 |
| Sequel Med Tech, LLC | 5 | $261 |
| Tandem Diabetes Care, Inc. | 8 | $214 |
| Lilly USA, LLC | 11 | $210 |
| RECORDATI_RARE_DISEASES_INC. | 8 | $157 |
| SANOFI-AVENTIS U.S. LLC | 9 | $156 |
| Amneal Pharmaceuticals LLC | 13 | $151 |
| Radius Health, Inc. | 5 | $124 |
| Ascendis Pharma Endocrinology Inc | 4 | $108 |
Products named: Ozempic, TWIIST, t:slim X2 Insulin Pump with Control-IQ, TEPEZZA, Wegovy, ISTURISA, TZIELD, UNITHROID.
Industry payments across TX — which companies pay providers there.
